According to ANI Pharmaceuticals's latest financial reports the company's total debt is $0.28 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $0.28 B | -0.3% |
2022-12-31 | $0.28 B | -0.3% |
2021-12-31 | $0.28 B | 54.76% |
2020-12-31 | $0.18 B | -0.03% |
2019-12-31 | $0.18 B | 1.49% |
2018-12-31 | $0.18 B | -9.18% |
2017-12-31 | $0.20 B | 67.03% |
2016-12-31 | $0.12 B | 6.36% |
2015-12-31 | $0.11 B | 6.46% |
2014-12-31 | $0.10 B | |
2013-12-31 | $N/A | -100% |
2012-12-31 | $7.88 M | -54.53% |
2011-12-31 | $17.33 M | -6.53% |
2010-12-31 | $18.54 M | 11.22% |
2009-12-31 | $16.67 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Novartis NVS | $26.34 B | 9,123.26% | ๐จ๐ญ Switzerland |
Pfizer PFE | $70.84 B | 24,699.68% | ๐บ๐ธ USA |
Cardinal Health CAH | $4.72 B | 1,553.31% | ๐บ๐ธ USA |
Jazz Pharmaceuticals JAZZ | $5.79 B | 1,927.38% | ๐ฎ๐ช Ireland |
Evoke Pharma
EVOK | $5 M | -98.25% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $2.54 M | -99.11% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $20.15 B | 6,954.67% | ๐ฎ๐ฑ Israel |
Royalty Pharma RPRX | $6.13 B | 2,047.69% | ๐ฌ๐ง UK |
Lannett Company LCI | $0.63 B | 123.91% | ๐บ๐ธ USA |